DSM Capital Partners LLC Sells 3,383 Shares of Stryker Corporation $SYK

Key Points

• DSM Capital Partners reduced its Stryker position by 11.7%, selling 3,383 shares and retaining 25,544 shares valued at approximately $8.04 million. Institutional investors collectively own 77.09% of the company.
• Analysts maintain a favorable outlook, with Stryker holding a consensus “Moderate Buy” rating and an average price target of $386.28, despite several recent target reductions.
• Stryker exceeded quarterly earnings expectations, reporting $3.69 in EPS and $6.59 billion in revenue, while revenue grew 9.4% year over year. The company also declared a quarterly dividend of $0.88 per share, representing a 1.0% annualized yield.

DSM Capital Partners LLC cut its position in Stryker Corporation (NYSE:SYK - Free Report) by 11.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,544 shares of the medical technology company's stock after selling 3,383 shares during the quarter. DSM Capital Partners LLC's holdings in Stryker were worth $8,042,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. VanderPol Investments L.L.C. boosted its holdings in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after acquiring an additional 28 shares during the period. KCM Investment Advisors LLC grew its position in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC increased its stake in shares of Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock worth $159,000 after purchasing an additional 28 shares during the period. Tcfg Wealth Management LLC increased its stake in shares of Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock worth $403,000 after purchasing an additional 29 shares during the period. Finally, West Michigan Advisors LLC lifted its position in shares of Stryker by 0.4% during the 4th quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company's stock worth $2,631,000 after purchasing an additional 30 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Analysts Set New Price Targets

SYK has been the subject of several recent analyst reports. Evercore set a $350.00 target price on Stryker in a research note on Monday, July 6th. UBS Group started coverage on Stryker in a research report on Tuesday, July 28th. They issued a "buy" rating and a $400.00 price target on the stock. JPMorgan Chase & Co. cut their price target on Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Piper Sandler reduced their price objective on Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Finally, Leerink Partners lowered their price objective on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a research note on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $386.28.

Stryker Price Performance

Shares of SYK stock opened at $338.80 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.17 and a beta of 0.76. The stock has a 50 day moving average of $324.61 and a two-hundred day moving average of $333.57. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker's payout ratio is currently 36.48%.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm's stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 4.60% of the company's stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source